Skip to main content
. 2021 Nov 24;20:227. doi: 10.1186/s12933-021-01422-3

Table 1.

Baseline characteristics

N Total
N = 294 057
Low
 < 3.9 mmol/L
n = 7 408 (2.5%)
Normal
3.9–6.0 mmol/L
n = 266 943 (90.8%)
IFG
6.1–6.9 mmol/L
n = 9 682 (3.3%)
Undiagnosed DM
 ≥ 7.0 mmol/L
n = 5 457 (1.9%)
Diagnosed DM
n = 4 567 (1.6%)
Age (years) 294 057

47

(40–56)

43

(36–51)

47

(39–55)

54

(46–61)

57

(49–64)

53

(45–60)

Sex, female 294 057

135 562

(46.1)

4 382

(59.2)

124 497 (46.6)

3 300

(34.1)

1 646

(30.2)

1 737

(38.0)

Blue collar worker 286 058

157 549

(55.1)

4 090

(56.8)

142 258

(54.7)

5 464

(58.3)

3 084

(59.6)

2 653

(60.1)

Born in Nordic countries 294 057

270 242

(92.1)

6854

(92.5)

245 489

(92.0)

8 878

(91.7)

4 884

(89.5)

4 147

(90.8)

Referred from occupational health care 259 549

193 573

(74.6)

5 187

(79.0)

177 643

(75.4)

5 585

(65.6)

2 710

(57.2)

2 448

(59.9)

BMI (kg/m2) 55 390

24.0

(21.8–26.5)

22.4

(20.6–24.6)

24.0

(21.8–26.3)

26.5

(24.2–29.5)

28.0

(25.5–30.9)

26.6

(23.4–29.8)

Kidney disease 294 057

288

(0.1)

9

(0.1)

257

(0.1)

9

(0.1)

2

(0.0)

11

(0.2)

Liver disease 294 057

1 102

(0.4)

38

(0.5)

862

(0.3)

65

(0.7)

51

(0.9)

86

(1.9)

Asthma/COPD 294 057

2 026

(0.7)

63

(0.9)

1 740

(0.7)

93

(1.0)

55

(1.0)

75

(1.6)

History of cancer 294 057

6 550

(2.2)

131

(1.8)

5 812

(2.2)

287

(3.0)

196

(3.6)

124

(2.7)

Mitral stenosis 294 057

34

(0)

0

30

(0)

1

(0)

2

(0)

1

(0)

Mechanical

valve-replacement

294 057

25

(0)

0

24

(0)

1

(0)

0 0
Fasting glucose, mmol/L 294 057

4.8

(4.5–5.2)

3.7

(3.5–3.8)

4.8

(4.5–5.2)

6.3

(6.2–6.6)

8.2

(7.3–10.4)

8.3

(6.2–11.9)

Fructosamine, mmol/L 242 205

2.1

(2.0–2.2)

2.0

(1.9–2.2)

2.1

(2.0–2.2)

2.2

(2.0–2.3)

2.5

(2.2–2.9)

2.6

(2.3–3.1)

Total cholesterol, mmol/L 294 057

5.7

(5.0–6.4)

5.4

(4.7–6.1)

5.7

(5.0–6.4)

6.0

(5.3–6.8)

6.0

(5.3–6.8)

5.8

(5.0–6.6)

Triglyceride level, mmol/L 294 057

1.0

(0.7–1.5)

0.9

(0.6–1.2)

1.0

(0.7–1.5)

1.5

(1.0–2.2)

1.9

(1.3–2.8)

1.5

(1.0–2.4)

Apo-B/Apo-A1 ratio 294 057

0.89

(0.71–1.10)

0.82

(0.67–1.01)

0.88

(0.71–1.09)

0.96

(0.79–1.21)

1.05

(0.85–1.28)

0.97

(0.78–1.22)

Haemoglobin, g/L 73 119

141.0

(133.0–150.0)

138.0

(129.0–147.0)

141.0

(132.0–150.0)

146.0

(138.0–154.0)

149.0

(140.0-

157.0)

145.0

(136.0–154.0)

WBC, 10^9/L 67 806

6.1

(5.1–7.4)

6.1

(5.1–7.6)

6.1

(5.1–7.3)

6.6

(5.6–7.9)

6.9

(5.8–8.3)

6.6

(5.5–8.0)

Subjects with eGFR below 60 ml/min/1.73 m2 283 448 10 173 (3.5) 180 (2.4) 8 435 (3.2) 698 (7.2) 559 (10.3) 301 (6.6)
Uric acid, umol/L 278 499

287.0

(240.0–337.0)

262.0

(218.0–311.0)

286.0

(239.0–335.0)

335.0

(285.0–389.0)

321.0

(271.0–380.0)

286.0

(235.0–345.0)

CRP, mg/L 139 257

4.0

(1.0–6.0)

3.0

(1.0–6.0)

4.0

(1.0–6.0)

4.0

(3.0–7.0)

4.0

(2.0–8.0)

4.0

(2.0–7.0)

Haptoglobin, g/L 234 448

1.0

(0.9–1.2)

1.0

(0.8–1.2)

1.0

(0.9–1.2)

1.1

(1.0–1.4)

1.2

(1.0–1.4)

1.1

(0.9–1.3)

Categorical variables presented as absolute and relative (percentages) frequencies and continuous variables as median and interquartile range

IFG Impaired fasting glucose, DM Diabetes mellitus, COPD Chronic obstructive pulmonary disease, WBC White blood cells